RBC Lifts Eli Lilly Price Target on Expected 'Strong' Q2 Performance of Obesity Drugs
() -- RBC Capital Markets expects Eli Lilly (LLY.SW) to report a "strong" performance from obesity drugs Zepbound and Mounjaro when it publishes its second-quarter results on Aug. 5. The US-based pharmaceutical company's total revenue is forecast to reach $20.74 billion in the quarter, higher than the Visible Alpha con